Breaking News Instant updates and real-time market news.

KITE

Kite Pharma

$48.35

-2.21 (-4.37%)

, JUNO

Juno Therapeutics

$22.12

-0.89 (-3.87%)

07:26
11/29/16
11/29
07:26
11/29/16
07:26

Kite Pharma benefits from program delays at Juno, says Canaccord

Canaccord analyst John Newman believes Kite Pharma (KITE) will benefit from the program delays at Juno Therapeutics (JUNO). Two deaths in Juno's Phase 2 ROCKET trial may prompt safety questions for its drug to be used in refractory NHL, which raises the upside potential for Kite when its presents its data at the ASH conference. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.

KITE

Kite Pharma

$48.35

-2.21 (-4.37%)

JUNO

Juno Therapeutics

$22.12

-0.89 (-3.87%)

  • 03

    Dec

  • 03

    Dec

KITE Kite Pharma
$48.35

-2.21 (-4.37%)

10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
JUNO Juno Therapeutics
$22.12

-0.89 (-3.87%)

11/25/16
SBSH
11/25/16
NO CHANGE
Target $34
SBSH
Buy
Citi still bullish on Juno's technology despite clinical hold
Citi analyst Robyn Karnauskas says she remains bullish on Juno Therapeutics' technology after the company voluntarily placed its JCAR015 ROCKET program on clinical hold following cerebral edema in two patients last week. Juno has the best data in both adult and pediatric acute lymphoblastic leukemia, Karnauskas told investors Wednesday in a research note. She expects the company's therapies will get used despite the safety risks and believes Juno will be able to find ways to slow the rate of cell proliferation and reduce toxicity. The analyst lowered her price target for Juno shares to $34 from $45 and kept a Buy rating on the name. Juno closed Wednesday down $7.32 to $22.56.
11/25/16
11/25/16
DOWNGRADE
Target $25

Hold
Juno Therapeutics downgraded to Hold at SunTrust
As previously reported, SunTrust analyst Peter Lawson downgraded Juno Therapeutics to Hold from Buy due to the reduced visibility and increased uncertainty that comes from the two additional deaths in the company's ROCKET trial of JCAR015. Citing the renewed issues with JCAR015, Lawson decreased his probability of success across the company's pipeline and lowered his price target for Juno shares to $25 from $48.
11/25/16
MAXM
11/25/16
NO CHANGE
Target $34
MAXM
Buy
Juno still has significant opportunity in 'no-option population,' says Maxim
Maxim analyst Jason McCarthy removed JCAR015 in adult ALL from his model for Juno Therapeutics after the company placed its ROCKET study on clinical hold for the second time following two additional patient deaths. Accordingly, the analyst lowered his price target on Juno shares to $34 from $50. However, McCarthy keeps a Buy rating on Juno shares, as he still believes CAR-T technology, and the company, has a "significant opportunity in the no-option population" and that regulators will agree when evaluating treatments intended to help patients that will otherwise die.
11/28/16
LEER
11/28/16
NO CHANGE
Target $34
LEER
Outperform
Juno Therapeutics price target lowered to $34 from $45 at Leerink
Leerink analyst Michael Schmidt lowered his price target for Juno Therapeutics to $34 from $45 following news that the pivotal ROCKET trial of its JCAR015 product candidate in adult acute lymphocytic leukemia has been placed on a clinical hold due to safety concerns. The analyst believes the future of the program is now increasingly uncertain as the company's management is trying to better understand the therapeutic window of JCAR015, raising the question of whether it moved into a pivotal trial too fast. Schmidt reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.